Go Pro

Tango Therapeutics (TNGX) 10K Form and Latest SEC Filings 2026

Tango Therapeutics logo
$23.34 -1.94 (-7.67%)
As of 08/28/2026 04:00 PM Eastern

Latest Tango Therapeutics SEC Filings & Recent Activity

Tango Therapeutics (NASDAQ:TNGX) has submitted 316+ documents to the U.S. Securities and Exchange Commission (SEC) since 2020. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Tango Therapeutics's financial statements. The most recent filing was a Form SCHEDULE 13G/A submitted on August 14, 2026.

Form 4
Tango Therapeutics, Inc. Reports Ownership Change on Jul. 2, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Tango Therapeutics Files Current Report on Aug. 11, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Tango Therapeutics Files Quarterly Report on Aug. 11, 2026

The 10-Q contains Tango Therapeutics's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Tango Therapeutics SEC Filing History

Browse Tango Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
08/14/2026 10:05 AM
Tango Therapeutics (1819133) Subject
Woodline Partners LP (1784547) Filed by
Form SCHEDULE 13G/A
08/14/2026 7:23 AM
FARALLON CAPITAL MANAGEMENT, L.L.C. (909661) Filed by
Tango Therapeutics (1819133) Subject
Form SCHEDULE 13G/A
08/12/2026 11:01 AM
Adage Capital Management, L.P. (1535978) Filed by
Tango Therapeutics (1819133) Subject
Form SCHEDULE 13G/A
08/11/2026 4:10 PM
Tango Therapeutics (1819133) Filer
Form 424B5
08/11/2026 4:13 PM
Tango Therapeutics (1819133) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/11/2026 6:12 AM
Tango Therapeutics (1819133) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/11/2026 6:20 AM
Tango Therapeutics (1819133) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/07/2026 5:41 AM
Tango Therapeutics (1819133) Filer
Form 8-K/A
08/06/2026 4:30 PM
Tango Therapeutics (1819133) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/03/2026 3:47 PM
Crystal Adam (1825445) Reporting
Tango Therapeutics (1819133) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/02/2026 6:23 PM
Crystal Adam (1825445) Reporting
Tango Therapeutics (1819133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/23/2026 5:10 PM
Azelby Robert (1656998) Reporting
Tango Therapeutics (1819133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/23/2026 5:04 PM
Azelby Robert (1656998) Reporting
Tango Therapeutics (1819133) Issuer
Form 3
Initial statement of beneficial ownership of securities  
06/23/2026 4:19 PM
Tango Therapeutics (1819133) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/17/2026 3:45 PM
NEXTECH CROSSOVER I SCSP (1894038) Reporting
Tango Therapeutics (1819133) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/11/2026 5:00 PM
Beckman Daniella (1513422) Reporting
Tango Therapeutics (1819133) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/10/2026 4:22 PM
Tango Therapeutics (1819133) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/10/2026 4:21 PM
Tango Therapeutics (1819133) Filer
Form 424B5
06/10/2026 3:45 PM
Beckman Daniella (1513422) Reporting
Tango Therapeutics (1819133) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/09/2026 8:03 PM
Tango Therapeutics (1819133) Subject
Form FWP
06/08/2026 5:08 PM
Ketchum John B (1991806) Reporting
Tango Therapeutics (1819133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/08/2026 4:55 PM
Rothenberg Mace (1873988) Reporting
Tango Therapeutics (1819133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/08/2026 5:01 PM
Calhoun Lesley Ann (1730866) Reporting
Tango Therapeutics (1819133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/08/2026 4:49 PM
Lee Sung (1793200) Reporting
Tango Therapeutics (1819133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/08/2026 3:16 PM
Tango Therapeutics (1819133) Filer
Form 424B5
06/08/2026 6:15 AM
Tango Therapeutics (1819133) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/04/2026 4:19 PM
Tango Therapeutics (1819133) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/03/2026 5:37 PM
Crystal Adam (1825445) Reporting
Tango Therapeutics (1819133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/15/2026 8:16 AM
Tango Therapeutics (1819133) Subject
Woodline Partners LP (1784547) Filed by
Form SCHEDULE 13G/A
05/15/2026 7:34 AM
RTW INVESTMENTS, LP (1493215) Filed by
Tango Therapeutics (1819133) Subject
Form SCHEDULE 13G
05/13/2026 3:16 PM
Tango Therapeutics (1819133) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/13/2026 8:18 AM
Adage Capital Management, L.P. (1535978) Filed by
Tango Therapeutics (1819133) Subject
Form SCHEDULE 13G/A
05/11/2026 7:49 AM
Farallon Capital Partners, L.P. (1175707) Filed by
Tango Therapeutics (1819133) Subject
Form SCHEDULE 13G/A
05/08/2026 8:22 AM
Tango Therapeutics (1819133) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/06/2026 10:40 AM
FMR LLC (315066) Filed by
Tango Therapeutics (1819133) Subject
Form SCHEDULE 13G
05/05/2026 6:46 PM
Gall Matthew (1816194) Reporting
Tango Therapeutics (1819133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2026 6:47 PM
Crystal Adam (1825445) Reporting
Tango Therapeutics (1819133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2026 1:39 PM
Invus Global Management, LLC (2005369) Filed by
Tango Therapeutics (1819133) Subject
Form SCHEDULE 13G/A
05/01/2026 4:26 PM
Lee Sung (1793200) Reporting
Tango Therapeutics (1819133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2026 3:48 PM
Crystal Adam (1825445) Reporting
Tango Therapeutics (1819133) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/24/2026 3:15 PM
Gall Matthew (1816194) Reporting
Tango Therapeutics (1819133) Issuer
Form 3
Initial statement of beneficial ownership of securities  
Why Boston Ships In Natural Gas It Already Has at Home (Ad)

A tanker called the Iberica Knutsen once sailed 2,272 miles from Trinidad and Tobago to deliver liquefied natural gas to Boston. The odd part: the Marcellus Shale, one of the largest natural gas reserves in the world, sits just a few hundred miles away. Porter Stansberry spent years digging into why this happens and what it means for the American energy system.tc pixel

Uncover the full story behind Boston's costly LNG imports
04/24/2026 3:15 PM
Newcomb Jessica (2130408) Reporting
Tango Therapeutics (1819133) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/17/2026 6:42 AM
Tango Therapeutics (1819133) Filer
Form DEFA14A
04/17/2026 6:44 AM
Tango Therapeutics (1819133) Filer
Form ARS
04/17/2026 6:12 AM
Tango Therapeutics (1819133) Filer
Form DEF 14A
04/16/2026 7:14 PM
Crystal Adam (1825445) Reporting
Tango Therapeutics (1819133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 8:19 AM
Tango Therapeutics (1819133) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/02/2026 7:09 PM
Crystal Adam (1825445) Reporting
Tango Therapeutics (1819133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/27/2026 7:06 PM
Crystal Adam (1825445) Reporting
Tango Therapeutics (1819133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/25/2026 3:24 PM
Crystal Adam (1825445) Reporting
Tango Therapeutics (1819133) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/05/2026 3:52 PM
Crystal Adam (1825445) Reporting
Tango Therapeutics (1819133) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/05/2026 6:30 AM
Tango Therapeutics (1819133) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/05/2026 6:10 AM
Tango Therapeutics (1819133) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/05/2026 6:15 AM
Tango Therapeutics (1819133) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/27/2026 5:54 PM
Crystal Adam (1825445) Reporting
Tango Therapeutics (1819133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 5:29 PM
EcoR1 Capital, LLC (1587114) Filed by
Tango Therapeutics (1819133) Subject
Form SCHEDULE 13G/A
02/13/2026 10:47 AM
Invus Global Management, LLC (2005369) Filed by
Tango Therapeutics (1819133) Subject
Form SCHEDULE 13G/A
02/12/2026 8:11 AM
Adage Capital Management, L.P. (1535978) Filed by
Tango Therapeutics (1819133) Subject
Form SCHEDULE 13G
02/06/2026 3:11 PM
FARALLON PARTNERS L L C/CA (1040153) Filed by
Tango Therapeutics (1819133) Subject
Form SCHEDULE 13G/A
02/04/2026 7:09 PM
Tango Therapeutics (1819133) Issuer
Weber Barbara (1800670) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/04/2026 7:12 PM
Beckman Daniella (1513422) Reporting
Tango Therapeutics (1819133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/04/2026 7:02 PM
Crystal Adam (1825445) Reporting
Tango Therapeutics (1819133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/30/2026 1:44 PM
Tango Therapeutics (1819133) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G
01/21/2026 11:30 AM
BlackRock, Inc. (2012383) Filed by
Tango Therapeutics (1819133) Subject
Form SCHEDULE 13G
01/12/2026 5:15 AM
Peters Malte (1876563) Reporting
Tango Therapeutics (1819133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2026 8:10 AM
Tango Therapeutics (1819133) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/06/2026 3:05 PM
Lee Sung (1793200) Reporting
Tango Therapeutics (1819133) Issuer
Form 3
Initial statement of beneficial ownership of securities  
01/05/2026 6:09 AM
Tango Therapeutics (1819133) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/10/2025 11:15 PM
Tango Therapeutics (1819133) Filer
Form EFFECT
11/21/2025 3:15 PM
Tango Therapeutics (1819133) Subject
Third Rock Ventures IV, L.P. (1688327) Filed by
Form SCHEDULE 13D/A
11/21/2025 7:31 AM
Tango Therapeutics (1819133) Filer
Form S-3
Registration statement under Securities Act of 1933  
11/21/2025 7:34 AM
Tango Therapeutics (1819133) Filer
Form S-3ASR
11/21/2025 7:36 AM
Tango Therapeutics (1819133) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/13/2025 8:00 AM
Adage Capital Management, L.P. (1535978) Filed by
Tango Therapeutics (1819133) Subject
Form SCHEDULE 13G/A
11/12/2025 11:17 AM
Farallon Capital Partners, L.P. (1175707) Filed by
Tango Therapeutics (1819133) Subject
Form SCHEDULE 13G/A
11/04/2025 8:25 AM
Peters Malte (1876563) Reporting
Tango Therapeutics (1819133) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/04/2025 8:09 AM
Tango Therapeutics (1819133) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/04/2025 8:10 AM
Tango Therapeutics (1819133) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/28/2025 9:15 AM
Tango Therapeutics (1819133) Filer
Form D
Notice of Exempt Offering of Securities 
10/27/2025 3:15 PM
Tango Therapeutics (1819133) Issuer
Third Rock Ventures GP IV, L.P. (1688326) Reporting
Third Rock Ventures IV, L.P. (1688327) Reporting
TRV GP IV, LLC (1688325) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/24/2025 5:17 AM
Tango Therapeutics (1819133) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/24/2025 5:06 AM
Tango Therapeutics (1819133) Filer
Form 424B5
10/23/2025 4:10 PM
Tango Therapeutics (1819133) Subject
Third Rock Ventures IV, L.P. (1688327) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/23/2025 6:36 AM
Tango Therapeutics (1819133) Subject
Form FWP
10/23/2025 6:04 AM
Tango Therapeutics (1819133) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/29/2025 3:15 PM
Tango Therapeutics (1819133) Issuer
Third Rock Ventures GP IV, L.P. (1688326) Reporting
Third Rock Ventures IV, L.P. (1688327) Reporting
TRV GP IV, LLC (1688325) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/25/2025 3:58 PM
Tango Therapeutics (1819133) Subject
Third Rock Ventures IV, L.P. (1688327) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/22/2025 4:22 PM
Invus Global Management, LLC (2005369) Filed by
Tango Therapeutics (1819133) Subject
Form SCHEDULE 13G
09/17/2025 5:06 PM
Tango Therapeutics (1819133) Issuer
Third Rock Ventures GP IV, L.P. (1688326) Reporting
Third Rock Ventures IV, L.P. (1688327) Reporting
TRV GP IV, LLC (1688325) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/17/2025 9:29 AM
Tango Therapeutics (1819133) Subject
Third Rock Ventures IV, L.P. (1688327) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/09/2025 3:15 PM
Tango Therapeutics (1819133) Issuer
Third Rock Ventures GP IV, L.P. (1688326) Reporting
Third Rock Ventures IV, L.P. (1688327) Reporting
TRV GP IV, LLC (1688325) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
The cat is out the bag (Ad)

Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.tc pixel

Watch Porter Stansberry's full investigation into the Final Displacement now
09/08/2025 4:22 PM
Tango Therapeutics (1819133) Subject
Third Rock Ventures IV, L.P. (1688327) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/05/2025 5:08 PM
Tango Therapeutics (1819133) Subject
Third Rock Ventures IV, L.P. (1688327) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
(Data available from 1/1/2016 forward)

Tango Therapeutics SEC Filings - Frequently Asked Questions

Tango Therapeutics (TNGX) has submitted 316+ filings to the SEC since 2020. You can browse the complete history or filter by form type using the tools above.

Tango Therapeutics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Tango Therapeutics's financial statements page.

The most recent filing was a Form SCHEDULE 13G/A submitted on August 14, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


SEC filings for NASDAQ:TNGX are sourced directly from the U.S. Securities and Exchange Commission (SEC), with the most recent filing dated 8/14/2026. New filings are added as they're published.
From Our Partners